Document is current
Any future updates will be listed below
-
Authors
Xia, Ru-yu
Hu, Xiao-yang
Fei, Yu-tong
Willcox, Merlin
Wen, Ling-zi
Yu, Ming-kun
Zhang, Li-shan
Dai, Meng-yuan
Fei, Guang-he
Thomas, Mike
Francis, Nick
Wilkinson, Tom
Moore, Michael
Liu, Jian-ping
-
Funding
Funding for this research was provided by:
National Key Research and Development Project (2018YFE0102300)
Innovate UK (104287-610239)
NIHR Academic Clinical Lectureship (CL-2016-26-005)
- License Information
-
More Information
Article History
Received: 4 September 2019
Accepted: 14 April 2020
First Online: 24 May 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The authors declare that they have the following possible conflicts of interest. However, these conflicts of interest did not actually influence the design, analyses, and the reporting of this study in the current article.The Beijing University of Chinese Medicine obtained funding from the Ministry of Science and Technology of the People’s Republic of China for a project investigating the use of Chinese herbal medicine for the treatment of chronic obstructive pulmonary disease. The other partners in the project are the University of Southampton, Anhui Jiren Pharmaceutical Co., Ltd. (Jiren is the manufacturer of SFJD), and Phoenix Medical Ltd. The project is part of the “UK-China collaboration to tackle antimicrobial resistance”, funded by the UK and Chinese governments. Ru-yu Xia, Yu-tong Fei, Li-shan Zhang, Meng-yuan Dai, Guang-he Fei and Jian-ping Liu received this research funding from Ministry of Science and Technology of the People’s Republic of China; Xiao-yang Hu, Merlin Willcox, Mike Thomas, Nick Francis, Tom Wilkinson and Michael Moore received this research funding from Innovate-UK.Jian-ping Liu is a member of the editorial board (Section Editor) of BMC Complementary Medicine and Therapies.
